Completed PHASE1 INTERVENTIONAL NCT00118313

Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma

Evaluation of Different Adjuvants for the Transdermal Administration of a Peptide-Based Vaccine in Participants With High-Risk Melanoma

Sponsor: Craig L Slingluff, Jr

Conditions Melanoma (Skin)

Interventions adjuvant therapy dimethyl sulfoxide imiquimod incomplete Freund's adjuvant multi-epitope melanoma peptide vaccine sargramostim tetanus toxoid helper peptide

Updated 7 times since 2017 Last updated: Mar 26, 2020 Started: Nov 4, 2004 Primary completion: Jul 28, 2006 Completion: Jul 28, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00118313, this PHASE1 trial focuses on Melanoma (Skin) and remains completed. Sponsored by Craig L Slingluff, Jr, it has been updated 7 times since 2004, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Apr 2020 — Jan 2021 [monthly]

Completed PHASE1
Jun 2018 — Apr 2020 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Nov 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Craig L Slingluff, Jr
National Cancer Institute (NCI)

Data source: University of Virginia

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Charlottesville, United States